---
title: "US FDA begins “real-time” reporting of adverse event data"
date: "2025-09-01T17:47:02.000Z"
publishedDate: "1 septembre 2025"
summary: "The US Food and Drug Administration (FDA) recently announced that it has begun daily publication of adverse event data from the FDA Adverse Event Reporting System (FAERS). The agency says that &#8220;this represents a significant step forward in modernising the agency’s safety monitoring infrastructure and demonstrates its commitment to radical transparency and real-time protection of [&#8230;] The post US FDA begins &#8220;real-time&#8221; reporting of adverse event data appeared first on Vascular News ."
importance: ""
sourceUrl: "https://vascularnews.com/fda-begins-real-time-reporting-of-adverse-event-data/"
tags: ["France", "Actualité", "Vascular News — Latest"]
permalink: "/papers/2025-09-01-us-fda-begins-real-time-reporting-of-adverse-event-data"
imageUrl: "https://vascularnews.com/wp-content/uploads/sites/7/2025/09/FDA-2.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://vascularnews.com/fda-begins-real-time-reporting-of-adverse-event-data/"
---

![US FDA begins “real-time” reporting of adverse event data](https://vascularnews.com/wp-content/uploads/sites/7/2025/09/FDA-2.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://vascularnews.com/fda-begins-real-time-reporting-of-adverse-event-data/*

## L’essentiel

The US Food and Drug Administration (FDA) recently announced that it has begun daily publication of adverse event data from the FDA Adverse Event Reporting System (FAERS). The agency says that &#8220;this represents a significant step forward in modernising the agency’s safety monitoring infrastructure and demonstrates its commitment to radical transparency and real-time protection of [&#8230;] The post US FDA begins &#8220;real-time&#8221; reporting of adverse event data appeared first on Vascular News .

## Lien source

https://vascularnews.com/fda-begins-real-time-reporting-of-adverse-event-data/
